In gastric cancer, FENDRR affects cell malignant activity via the miR-214-3P/TET2 axis, whereas in prostate cancer, it reduces malignancy by competitively binding miR-18a-5p with Runt-related transcription factor 1 (RUNX1) (33, 40). The gene discussed is TET2; the disease is prostate carcinoma.